Global Oligonucleotide
Synthesis Market, by Equipment & Services (Equipment/Synthesizer,
Reagents, and Services (Oligo Synthesis, Modification, and Purification)), by
Technology (Column-based, and Microarray-based), by Nucleic Acid (DNA and RNA),
by Application (Drug Discovery and Therapeutics), by End User (Academic
Research Institutes, Diagnostic Laboratories, and Pharmaceutical-Biotechnology
Companies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa), is estimated to be valued at US$ 2,874.1 Million in
2020 and is expected to exhibit a CAGR of 11.3% during the forecast period
(2020-2027), as highlighted in a new report published by Coherent Market
Insights.
Key companies are focusing on
launching new services such as oligonucleotide synthesis, which is expected to
drive growth of the global oligonucleotide synthesis market during the forecast
period. For instance, in March 2017, Eurofins Genomics launched a DNA synthesis
service based on the company's next-generation synthesis platform in the U.S.
The service is designed to provide to supply small quantities of high-quality
oligonucleotides for molecular biology and synthetic biology.
Global Oligonucleotide Synthesis
Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus pandemic has
affected each and every market globally. There has been increasing demand for
effective treatment against COVID-19. Presently, pharmaceutical companies and
healthcare providers are focused on discovering more efficient use of
oligonucleotides and its application to prevent the spread of COVID-19.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/4257
For instance, in 2020, Innovative
Genomic Institute stated that they are working on aerosolized locked nucleic
acid modified antisense oligonucleotide that can be inhaled or nebulized for
the treatment of COVID-19 infection. Such innovations are generating an
interest amongst healthcare providers and driving them to fight against
COVID-19 pandemic. Thus, COVID-19 has affected the global oligonucleotide
synthesis market in a positive way.
Browse 47 Market Data Tables and
35 Figures spread through 167 Pages and in-depth TOC on “Oligonucleotide
Synthesis Market”- Global Forecast to 2027, by Equipment & Services
(Equipment/Synthesizer, Reagents, and Services (Oligo Synthesis, Modification,
and Purification)), by Technology (Column-based and Microarray-based), by
Nucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics),
by End User (Academic Research Institutes, Diagnostic Laboratories, and
Pharmaceutical - Biotechnology Companies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa).
Market players are focusing on
developing antisense oligonucleotides for the treatment of various diseases
such as Duchenne Muscular Dystrophy (DMD), which is expected to boost the
market growth during the forecast period. For instance, in December 2019,
Sarepta Therapeutics, Inc. received approval from the U.S. Food and Drug
Administration for VYONDYS 53 (golodirsen), an antisense oligonucleotide from
Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, indicated for
the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed
mutation amenable to exon 53 skipping.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/oligonucleotide-synthesis-market-4257
Key Takeaways of the Global Oligonucleotide
Synthesis Market:
The global oligonucleotide
synthesis market is expected to exhibit a CAGR of 11.3% during the forecast
period, owing to expansion of manufacturing facilities by market players. For
instance, in 2018, Corden Pharma GmbH (Germany) expanded its new overseas
commercial oligonucleotide active pharmaceutical ingredient manufacturing
facility at CordenPharma Colorado in the U.S., which will help to grow its
network in Europe and the U.S.
Among equipment & services,
equipment/synthesizer segment held a dominant position in the global
oligonucleotide synthesis market in 2019, owing to product launches by market
players. For instance, in April 2020 Biolytic Lab Performance Inc., a
manufacturer of oligo synthesizers and related lab accessories, introduced its
new oligo synthesizer, Dr. Oligo 768XLc, for throughput nucleic acid synthesis.
Key players operating in the
global oligonucleotide synthesis market include Thermo Fisher Scientific,
Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc.,
TriLink BioTechnologies, Inc, BioAutomation Corporation, Twist Bioscience,
Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio
Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka
Eurogentec S.A., and LGC, Biosearch Technologies
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/4257
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment